190 related articles for article (PubMed ID: 35903096)
21. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
[TBL] [Abstract][Full Text] [Related]
22. Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation.
Huang J; Pan Z; Wang L; Zhang Z; Huang J; Jiang C; Cai G; Yin T
Clin Exp Med; 2024 Jan; 24(1):22. PubMed ID: 38280072
[TBL] [Abstract][Full Text] [Related]
23. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG
Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
[TBL] [Abstract][Full Text] [Related]
24. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
[TBL] [Abstract][Full Text] [Related]
25. [Quantitative monitoring of mononucleated cell Epstein-Barr virus (EBV)-DNA for predicting EBV associated lymphoproliferative disorders after stem cell transplantation.].
Wang LH; Ren HY; Sun YH; Qiu ZX; Cen XN; Ou JP; Xu WL; Wang MJ; Wang WS; Li Y; Dong YJ; Yin Y; Liang ZY
Zhonghua Xue Ye Xue Za Zhi; 2010 Feb; 31(2):73-6. PubMed ID: 20302791
[TBL] [Abstract][Full Text] [Related]
26. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation.
Hoshino Y; Kimura H; Tanaka N; Tsuge I; Kudo K; Horibe K; Kato K; Matsuyama T; Kikuta A; Kojima S; Morishima T
Br J Haematol; 2001 Oct; 115(1):105-11. PubMed ID: 11722419
[TBL] [Abstract][Full Text] [Related]
27. Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.
Han SB; Bae EY; Lee JW; Jang PS; Lee DG; Chung NG; Jeong DC; Cho B; Lee SJ; Kang JH; Kim HK
Int J Hematol; 2014 Aug; 100(2):188-99. PubMed ID: 24981711
[TBL] [Abstract][Full Text] [Related]
28. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
29. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
[TBL] [Abstract][Full Text] [Related]
30. Association Between Cytomegalovirus and Epstein-Barr Virus Co-Reactivation and Hematopoietic Stem Cell Transplantation.
Li SS; Zhang N; Jia M; Su M
Front Cell Infect Microbiol; 2022; 12():818167. PubMed ID: 35402291
[TBL] [Abstract][Full Text] [Related]
31. Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation.
Gao F; Shi Z; Shi J; Luo Y; Yu J; Fu H; Lai X; Liu L; Yuan Z; Zheng Z; Huang H; Zhao Y
HLA; 2024 Jan; 103(1):e15320. PubMed ID: 38081622
[TBL] [Abstract][Full Text] [Related]
32. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
[TBL] [Abstract][Full Text] [Related]
33. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
[TBL] [Abstract][Full Text] [Related]
34. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
[TBL] [Abstract][Full Text] [Related]
36. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
38. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
Chen DB; Liu XY; Kong FZ; Jiang Q; Shen DH
J Clin Pathol; 2021 Nov; 74(11):697-703. PubMed ID: 34011618
[TBL] [Abstract][Full Text] [Related]
39. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
Zhou L; Lu DP
Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada.
Ratiu C; Dufresne SF; Thiant S; Roy J
Curr Oncol; 2024 May; 31(5):2780-2795. PubMed ID: 38785492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]